{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:28:07Z","timestamp":1786555687343,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T00:00:00Z","timestamp":1263340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Objective:\u2002Monitoring of bone disease in multiple myeloma is becoming increasingly important because bone\u2010protecting treatment with bisphosphonate is becoming restricted after the awareness of osteonecrosis of the jaw. Despite the potential of biochemical markers of bone remodeling to monitor dynamic bone turnover, they are not used in everyday practice. Here, we investigate their usefulness to detect imminent progressive osteolysis in relapsing patients with multiple myeloma. <jats:italic>Methods:<\/jats:italic> In an unselected cohort of 93 patients, we measured the bone resorption markers C\u2010terminal telopeptide of collagen type I (CTX\u2010I), C\u2010terminal cross\u2010linked telopeptide of type\u2010I collagen generated by MMPs (ICTP), N\u2010terminal cross\u2010linked telopeptide of type\u2010I collagen (NTX\u2010I), and the bone formation marker bone\u2010specific alkaline phosphatase (bALP) monthly for 2\u2003yr. Retrospectively, we identified 40 cases where patients had progressive disease. We investigated how the bone markers developed prior to disease progression. <jats:italic>Results:<\/jats:italic> We observed that CTX\u2010I and bALP changed significantly before progressive disease were recognized. More interestingly, these changes differed depending on whether concurrent progressive osteolysis was present. In patients with progressive osteolysis, there was a large increase in bone resorption which was not compensated by increased bone formation. In contrasts, patients with stable bone disease had only a slight increase in bone resorption which was compensated by concurrent increased bone formation. By calculating a patient\u2010specific CTX\u2010I\/bALP ratio, we quantified the risk a patient experiences if the ratio increases. <jats:italic>Conclusion:<\/jats:italic> By analyzing patient\u2010specific changes in the ratio of CTX\u2010I\/bALP, we might tailor treatment with bone\u2010protecting agents in the individual patient.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01417.x","type":"journal-article","created":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T14:12:01Z","timestamp":1263391921000},"page":"412-420","source":"Crossref","is-referenced-by-count":30,"title":["Multiple myeloma: changes in serum C\u2010terminal telopeptide of collagen type I and bone\u2010specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*"],"prefix":"10.1111","volume":"84","author":[{"given":"Thomas","family":"Lund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Marie","family":"Delaisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23326"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201394498"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3527"},{"key":"e_1_2_8_8_2","first-page":"5438","article-title":"Receptor activator of nuclear factor\u2010kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia AN","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.671"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1953"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4940"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4986"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034884"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2006.n.002"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1047"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1269"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06491.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90074.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650060615"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04050.x"},{"key":"e_1_2_8_24_2","first-page":"567","article-title":"Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma","volume":"89","author":"Abildgaard N","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(02)00246-2"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9"},{"key":"e_1_2_8_27_2","first-page":"394","article-title":"Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients","volume":"86","author":"Corso A","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.159"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.5.792"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/47.4.686"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2002.012"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.065005331.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403423"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403890"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2520.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2004.07.024"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030910"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.011"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11247"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.5.859"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.266"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115305"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02230356"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00046.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01417.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01417.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:36:45Z","timestamp":1698766605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01417.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01417.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01417.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}